In 2025, Bristol-Myers Squibb conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards.The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
| Metric (tonnes) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Waste Generated | 10,795a | 10,682a | 11,062a | |
Total Waste Recovered | 8,068a | 7,612a | 7,371a | |
Total Hazardous Waste Generated | 2,837a | 2,480a | 2,638a | |
Non-Hazardous Waste Disposed | 1,181a | 1,790a | 1,610a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, Bristol-Myers Squibb generated a total of 10,795metric tonnes of waste.a
Of this amount, 74.74% of Bristol-Myers Squibb's total waste generated was recovered through methods such as recycling, reuse, or composting, while 10.94% was disposed of through landfilling, incineration, or combustion.The remaining 14.32% was either treated using unspecified methods or not clearly categorized.a
In 2025, Bristol-Myers Squibb reported a total waste generation of 10,795 metric tonnes, of which 74.74% was recovered through recycling, reuse, or composting.This moderate level of recovery indicates that Bristol-Myers Squibb is taking steps toward improving its waste diversion practices, though there is still room to enhance recycling and recovery efforts.a
Since 2022, Bristol-Myers Squibb's total waste generation decreased by 8.32%, yet rose by 1.06% in 2025, potentially indicating a temporary operational shift or inconsistency in waste management outcomes.a
Over the same period, Bristol-Myers Squibb's waste recovery rate increased by 35.91%, including a 4.88% rise in 2025, indicating growing emphasis on circularity and improved operational practices for diverting waste from disposal.a
Overall, Bristol-Myers Squibb has reduced its waste footprint over time and continues to strengthen its recovery efforts, despite a recent uptick in waste output. This may reflect short-term operational shifts rather than a long-term reversal.
In 2025, Bristol-Myers Squibb generated a total of 10,795 metric tonnes of waste.a
Of this amount, 26.28% of Bristol-Myers Squibb's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment.73.73% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.a
Since 2022, Bristol-Myers Squibb's total waste generation fell by 8.32%, but rose by 1.06% in 2025, potentially reflecting a temporary surge in activity or inconsistency in waste control strategies.a
Over the same period, the share of hazardous waste in Bristol-Myers Squibb's total output increased by 72.21%, including a further 13.2% rise in 2025, suggesting a troubling upward shift toward more environmentally harmful waste streams that could raise compliance costs and environmental risks.a
Overall, Bristol-Myers Squibb had previously reduced its waste generation, but recent increases in both volume and hazardousness suggest potential reversals or emerging operational risks that warrant further investigation.a
In 2025, Bristol-Myers Squibb reported that 2,837 metric tonnes of its total waste output were classified as hazardous. This represents 26.28% of its overall waste generation.a
The company treated this hazardous waste using a combination of methods.A majority (75.11%) was diverted from disposal through recovery-oriented treatments such as recycling or reuse. This suggests that Bristol-Myers Squibb has established processes to reduce the environmental burden of its most harmful waste streams.a